LivaNova PLC
LIVNHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeLivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The $4.46B market capitalization puts LIVN squarely in mid-cap range for its industry. The company operates in two segments, Cardiopulmonary and Neuromodulation.
Market Cap
$4.46B
Beta
0.88
P/E (TTM)
24.08
P/E (Fwd)
17.27
EPS (TTM)
$3.36
EPS (Fwd)
$4.68
ROE
15.4%
ROA
5.0%
Cash
$516.6M
Total Debt
$351.9M
Free CF
$59.9M
52W Change
47.4%
Annual Financials
Cash vs Debt
Where LIVN stands vs its 150-day and 200-day moving averages
As of the October 14, 2026 close, LIVN finished 3.09% above its 150-day moving average ($74.08) and 6.34% above its 200-day moving average ($71.82). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LIVN overbought or oversold?
At the October 14, 2026 close, LIVN's RSI(14) was 46.8, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $516.6M in cash comfortably exceeding the $351.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $59.9M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 15.4% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 5.0% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $1.02B (2022) to $1.39B (2025), reflecting a 36% increase over the period.
As with any equity investment, LIVN carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. No single metric tells the full story. Reviewing LIVN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.